Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Tongluo Shengjin is a Traditional Chinese Medicine (TCM) herbal formulation developed as an in-hospital preparation by the Yueyang Integrated Traditional Chinese and Western Medicine Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the treatment of Sjögren's syndrome, an autoimmune disorder characterized by the destruction of exocrine glands leading to severe dryness of the eyes and mouth. The formula's name reflects its core therapeutic principles in TCM: clearing heat and detoxifying (Jiedu), unblocking the collaterals (Tongluo), and promoting the production of body fluids (Shengjin). Key botanical components include Peony (Shaoyao) and Glycyrrhizae (Gancao), which are studied in various compatibility ratios to optimize clinical efficacy and immunomodulatory effects. The drug is typically administered in a granule dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Tongluo Shengjin.